NCT04781374 is a Phase 2 clinical trial of Neratinib in Metastatic Prostate Adenocarcinoma, sponsored by Beth Israel Deaconess Medical Center.

Who is sponsoring NCT04781374?

NCT04781374 is sponsored by Beth Israel Deaconess Medical Center.

What drugs are being tested in NCT04781374?

Interventions in NCT04781374: Neratinib.

What condition does NCT04781374 study?

NCT04781374 studies Metastatic Prostate Adenocarcinoma, Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Cancer Metastatic.

Is NCT04781374 still recruiting?

NCT04781374 is currently withdrawn. Last updated 11 July 2023.

Last reviewed 2023-07-11 · How we verify

NCT04781374

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Withdrawn Phase 2 Last updated 11 July 2023

What this trial tests

Phase 2 trial testing Neratinib in Metastatic Prostate Adenocarcinoma. Withdrawn.

Timeline

21 May 2021

Primary endpoint
24 September 2021

24 September 2021

Quick facts

Lead sponsor	Beth Israel Deaconess Medical Center
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	21 May 2021
Primary completion	24 September 2021
Estimated completion	24 September 2021
Sites	3 locations across United States

Drugs / interventions tested

Neratinib — full drug profile →

Conditions studied

Metastatic Prostate Adenocarcinoma — all drugs for Metastatic Prostate Adenocarcinoma →
Castration-resistant Prostate Cancer — all drugs for Castration-resistant Prostate Cancer →
Prostate Cancer — all drugs for Prostate Cancer →
Prostate Cancer Metastatic — all drugs for Prostate Cancer Metastatic →

Sponsor

Beth Israel Deaconess Medical Center

Who can join

18 and older, male only, with Metastatic Prostate Adenocarcinoma or Castration-resistant Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is examining whether Neratinib has any activity in participants with prostate cancer that has spread and is no longer responding to hormonal treatment. \- The names of the study drug involved in this study is neratinib.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Increased ErbB2 Signaling Is an Early Adaptation to Androgen Signaling Inhibition and Persists in Castration-Resistant Prostate Cancer.
Owiredu J, Ersoy-Fazlioglu B, Poluben L, Calagua C, et al · · 2025 · PMID 40795068 · DOI 10.1158/1078-0432.ccr-22-3683

Verify or expand the search:

Other trials of Neratinib

Trials testing the same drug.

NCT06813079 — Using Tumor Models to Determine Treatments · Phase 2 · not yet recruiting
NCT05919108 — Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers · Phase 2 · recruiting
NCT05491057 — Treatment Patterns of Neratinib in HER2+ EBC in China · not yet recruiting
NCT05243641 — Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients W · Phase 1, PHASE2 · terminated
NCT04886531 — Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers · Phase 2 · recruiting

Other recruiting trials for Metastatic Prostate Adenocarcinoma

Currently open trials in the same condition.

NCT06931340 — Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati · Phase 3 · recruiting
NCT06236139 — Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate · Phase 1, PHASE2 · recruiting
NCT06145633 — Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer · Phase 2 · recruiting
NCT06039371 — Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA St · Phase 2 · recruiting
NCT05689021 — CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations · Phase 2 · active not recruiting

Other Beth Israel Deaconess Medical Center trials

Trials by the same sponsor.

NCT07352657 — Remote Alert Pathway To Optimize CaRe of Cardiac Implantable Electrical Devices: The RAPTOR-CIED Study (Main Phase) · NA · not yet recruiting
NCT07531602 — Effect of PEEP on Cardiac Function · NA · not yet recruiting
NCT07534683 — Primed to Thrive: Investigating the Combined Impact of Mindfulness Education and Meditation Practice on Psychological an · NA · not yet recruiting
NCT07277244 — Low-Intensity Mechanical Ventilation in the Operating Room: a Pilot Study · NA · enrolling by invitation
NCT06896474 — SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04781374 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beth Israel Deaconess Medical Center
Last refreshed: 11 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04781374.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing